Alzheimer¬ís Disease and Animal Models in RetrospectJames Oluwagbamigbe Fajemiroye*
Laboratório de Farmacologia de Produtos Naturais, Departamento de Ciências Fisiológicas, Instituto de Ciências Biológicas, Universidade Federal de Goiás, Brazil
- *Corresponding Author:
- James Oluwagbamigbe Fajemiroye
Laboratório de Farmacologia de Produtos Naturais
Departamento de Ciências Fisiológicas
Instituto de Ciências Biológicas
Universidade Federal de Goiás, Brazil
CP 131, CEP 74001-970, Goiânia, GO, Brazil
Tel: (62) 35211491
Fax: (62) 3521 1204
E-mail: [email protected]
Received date: August 13, 2014; Accepted date: September 28, 2014; Published date: September 30, 2014
Citation: Fajemiroye JO (2014) Alzheimer’s Disease and Animal Models in Retrospect. Med chem 4:701-703. doi:10.4172/2161-0444.1000215
Copyright: © 2014 Fajemiroye JO. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Alzheimer’s disease (AD) is one of the neurodegenerative diseases that affect millions of people worldwide. AD could rob patients of their ability to recall, reason and carry out executive functions. Pathophysiological studies of AD have revealed the gradual loss of neurons, function and ultimate death of neurons (apoptosis). Mutations, oxidative stress, excitotoxicity, infectious diseases are among the principal causes of neuronal degeneration. Despite the prescription of a wide range of drugs to treat AD, the emergence of effective treatments to halt the progress or reverse this disease has remained elusive for years. Series of preclinical studies have been developed to ensure better understanding of the neurobiology of AD and engender the discovery of new drugs. This review provides an overview on the pathophysiology, pharmacotherapy and preclinical models of AD in an attempt to bring together current research efforts, challenges, achievements and prospect for the discovery of drugs to treat AD. Pathophysiological evidences of this neurodegenerative disease has shown the involvement of multiple neural mechanisms. So far, the research approaches and treatment of this disease still remain largely unsatisfactory. However, there are possibilities of surmounting current challenges with new technology, diagnostic criteria and translational approach that effectively reflect clinical etiology of AD in experimental animals.